Navigation Links
ChanTest Announces Third User Meeting: Partnerships in Drug Discovery
Date:8/6/2013

Cleveland, OH (PRWEB) August 06, 2013

Partnerships between industry and vendors have a positive impact on the drug discovery industry when the right companies come together, as they allow for innovation and optimize the process of identifying the right drugs faster and more effectively. On Friday, September 27, 2013, ChanTest will host a third User Meeting: "Partnerships in Drug Discovery" to be held at the Westin Boston Waterfront Hotel, 425 Summer Street, Boston, MA.

The keynote speaker of this complimentary event will be Christopher Penland, Ph.D., Senior Director of Research at the Cystic Fibrosis Foundation, who will speak about the Foundation’s efforts to work with the scientific community to find new solutions for cystic fibrosis.Other presentations will highlight ion channels for pain drug discovery and neuropathology, the development of gut-targeted therapeutics, and strategies for merging automated patch clamp techniques with high-throughput screening.

"We are again looking forward to bringing together a range of experts from safety and discovery labs to highlight their work and the value of their collaborations with ChanTest," explained Chris Mathes, Ph.D., Chief Commercial Officer at ChanTest.

The event is co-sponsored by Acea Biosciences, Axion Biosystems, AxioGenesis, Battelle, Cellular Dynamics International, Molecular Devices, Renovo Neural, Sophion and Sygnature Discovery.

Register to attend.

Friday, September 27, 2013
3rd ChanTest User Meeting: Partnerships in Drug Discovery
Westin Boston Waterfront Hotel
425 Summer Street
Boston, MA 02210

FURTHER INFORMATION
ChanTest
14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax
info(at)chantest(dot)com

Contact for Media Inquiries:
Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
cmathes(at)chantest(dot)com
http://www.chantest.com

About ChanTest® – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 300 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs.

ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and nonclinical cardiac risk assessment service portfolio is the most comprehensive commercially available today.

Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in an independent survey over the past eight years. ChanTest is based in Cleveland, Ohio. Visit http://www.chantest.com to learn more about what we do.

Read the full story at http://www.prweb.com/releases/2013/8/prweb10997636.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. ChanTest Announces ChansPorter™ Assays to Accelerate Drug Development for Cystic Fibrosis Patients
2. New Teeth Whitening Procedure Effective On Teeth of Elderly, and Darkly Stained by Tetracycline, San Antonio Cosmetic Dentist Edward Camacho Announces
3. Diet Doc Weight Loss Plans Announces New Fat Burning Foods That Allow Patients to Lose Weight Fast and Decrease Bone Marrow Fat
4. Migraine Research Foundation Announces Newly Expanded and Updated Headache Doctor Lists
5. Leading Shopping Cart Software Expert, Shopping Cart Elite, Officially Announces The Launch Of Ebridalsuperstore.com.
6. Help Desk Software Provider iSupport Software Announces Version 12.5
7. hCGTreatments / Diet Doc Prescription Weight Loss Plans Announces New Quick Weight Loss Supplement 7-Keto DHEA Designed To Accelerate Results Naturally
8. hCGTreatments / Diet Doc Weight Loss Diets Announces Medical Diet Plans Designed to Promote Fast Weight Loss While Lowering Cholesterol Levels
9. Internet Marketing Firm Web-Op Announces Launch of KingSupplements.com
10. Clay Park Tower Apartments, One of San Francisco’s Top Pacific Heights Apartment Complexes, Announces 100% Occupancy
11. Spectrum Surgical Announces Dual-Chuck® Orthopedic Pin Insertion Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
Breaking Medicine Technology: